Media OutReach
Uni-Bio Science Group Limited Announces 2024 Annual Results
Record-Breaking Revenue of HK$553.0M and Net Profit of HK$82.8M First-ever Dividend was HK$0.277 Cents Per Share Strengthening Presence in Osteoporosis, Ophthalmology, and Aesthetic Medical Markets
HONG KONG SAR – EQS Newswire – 27 March 2025 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2024 (the “Period”).
Key Accomplishments in 2024
During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:
1. The Group recorded a 14.1% year-on-year (“YoY”) increase in revenue, reaching approximately HK$553.0 million. With its approval in January 2024 and subsequent launch in March 2024, Bogutai® achieved sales of HK$62.9 million, exceeding initial expectations.
2. Profit for the Year soared by16.8% YoY to approximately HK$82.8 million, marking a historic high. These results reaffirm the Group’s solid market position and its ability to deliver sustainable, high-quality growth as a leading biopharmaceutical company.
3. The board of directors (“Board”) has declared a dividend payment for 2024 of HK$0.277 cents per share, marking the historic first for the Company. This is particularly encouraging, as it represents an important milestone for a research-oriented biopharmaceutical company. The Board is also pleased to announce the approval and adoption of a dividend payout policy of no less than 20% of its net profit for the current year.
4. In January 2024, the China National Medical Products Administration (“NMPA”) officially approved the launch of Bogutai®, marking a major breakthrough for the Group in osteoporosis and orthopedic disease management. Since its market debut in early 2024, Bogutai® has gained remarkable traction, achieving a patient retention rate exceeding 70%.
5. In December 2024, the Group successful launch its self-developed medical aesthetics product, 肌顏態®. The recombinant collagen dressing, developed in collaboration with Chongqing Minji Medical Device Co., Ltd., received Class II medical device approval, reinforcing the Group’s commitment to innovative skin repair solutions.
6. In January 2024, the NMPA officially accepted the marketing application for Diquafosol Sodium eye drops, marking a key milestone in the Group’s ophthalmology drug pipeline. During the Year, the Group has already submitted additional data to the Center for Drug Evaluation (CDE). Diquafosol Sodium is expected to receive the marketing approval in the first half of 2025.
7. During the Year, the Group completed the pharmaceutical research and pre-Bioequivalence studies of Esaconazole sulfoate capsules. The formal Bioequivalence trials has been initiated in 2025 to accelerate the launch process.
8. In May 2024, the Group cooperated with Great Bay Bio (GBB) and Pebble Accelerator, a subsidiary of Tigermed to joint development of innovative weight reduction drugs, aiming to revolutionize the treatment of obesity. Through this collaboration, we seek to establish a comprehensive ecological industry chain, spanning from target discovery to antibody generation, druggability verification, process development, clinical pipeline, and ultimately, commercialization.
Annual Results
In 2024, the Group recorded a revenue of approximately HK$553.0 million, representing an increase of 14.1% YoY. The increase in revenue was mainly attributable to the favorable sales performance of the Group’s newly launched product Bogutai®. The Group’s newly launched product Bogutai® achieved sales of HK$62.9 million, exceeding initial expectations. Pinup® recorded a decrease of 2.9% in revenue from approximately HK$247.4 million to approximately HK$240.3 million for the Year. During the Year, the Group was re-selected for the centralized procurement, with a validity period of two years. However, the Group adopted a more selective approach to supplying hospitals in response to certain local policy adjustments. During the Year, revenue generated from GeneTime® was approximately HK$197.9 million, representing an increase of 6.7% YoY. The increase was attributed to the expansion of the Group’s hospital network and additional sales channels beyond hospitals, such as pharmacies and e-commerce platforms. GeneSoft® recorded an increase in revenue from approximately HK$41.3 million to approximately HK$42.5 million, representing an increase of 2.9% YoY. Revenue from Boshutai® declined from approximately HK$10.4 million to approximately HK$9.4 million, representing a decrease of 10.2%. During the Year, Boshutai® was successfully included in the centralized procurement by the Henan Seventeen Provinces Alliance and the procurement validity period is set for two years, which secured the Group with new in-hospital orders.
Prospects
Recent advancements in biotechnology, coupled with strong government support, position China’s pharmaceutical landscape for substantial growth, with a projected compound annual growth rate (CAGR) of 7.5% from 2024 to 2032, according to the IMARC Group. This expansion is driven by technological innovations and a growing elderly population increasingly susceptible to chronic conditions such as diabetes, which boosts pharmaceutical demand. Concurrently, the aesthetic medical sector is emerging as a significant market force, with forecasts indicating a CAGR of 10% to 15% from 2024 to 2027, primarily fueled by rising beauty standards and increased spending among individuals with moderate to high incomes. With the two industries being the Group’s core R&D focuses going forward, it showcases a great potential for the Group to rapidly grow and capture the market shares.
Mr. Kingsley Leung, Chairman of Uni-Bio Science commented, “I am proud to announce that we have reached significant milestones this year, both financially and operationally. As our efforts begin to bear fruit, I am deeply grateful for the unwavering, long-term support of our shareholders. In recognition of this, I am delighted to share two landmark decisions: the declaration of our inaugural dividend and the establishment of a forward-looking dividend payout policy of no less than 20% of its net profit for the current year. These actions reaffirm our steadfast commitment to delivering on our objectives while creating and sustaining value for our shareholders.
Looking forward, we remain steadfast in our commitment to innovation and seizing opportunities within both the pharmaceutical and aesthetic medical sectors. Our vision has consistently focused on diversifying our product offerings while leveraging our strengths in endocrinology, ophthalmology, and dermatology. We are delighted to announce the successful launch of Bogutai® Following this milestone, we will continue to develop best-in-class products, including a PTH microneedle formulation that is less invasive and offers higher bioavailability, as well as a novel antibody drug for weight loss. Significant advancements have also been made in our series of EGF products. Preparations for pilot plant testing of the EGF hydrogel are underway, and Diquafosol Sodium Eye Drop slated for launch in the second quarter of 2025. Additionally, The formal Bioequivalence trials for Esaconazole sulfoate capsules has been initiated in 2025 to accelerate the launch process.
In the aesthetic medical segment, we are excited about the launch of肌顏態® in late December 2024. Building on this momentum, we will accelerate the introduction of other new product lines in 2025 based on Skbrella™ FN. Additionally, we plan to introduce collagen and beauty peptides as advanced skincare raw materials this year. By leveraging our expertise in GeneTime® and 肌顏態®, we aim to create a comprehensive skincare solution for emergency skin repair and stabilization. To foster our product innovation, we are utilizing two new key technology platforms: advanced synthetic biology platform and hydrogel technology. These platforms are expected to drive our product expansion.
To enhance our reach and support product launches, we are expanding our sales channels beyond traditional public and private hospital networks to include pharmacies, online platforms, and aesthetic medical institutions. We are also exploring international markets to bolster our global presence. By adopting a diversified distribution strategy, the Group aims to secure future sales growth while reducing its dependence on regional markets and traditional channels. In support of our company’s growth, the infrastructure for our new factory in Dongguan was fully completed in 2024, marking a significant milestone in our expansion plans. A state-of-the-art BFS packaging line has also been featured, which we believe will enable the Group to command a premium in the market. With these strategic focuses and our commitment to rapid advancement, the Group is well-positioned to solidify its leadership in these dynamic industries and achieve lasting success in the years ahead.”
Hashtag: #Uni-BioScience
The issuer is solely responsible for the content of this announcement.
About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and sales of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology.
Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.
For further information, please contact: [email protected]
CareerSense Matters in Today’s Job Market
The global workforce is evolving rapidly. Automation, digitalisation, and emerging technologies are creating new opportunities while presenting new challenges. Navigating this landscape requires more than academic credentials; it demands self-awareness, adaptability, and strategic planning.
CareerSense addresses these needs by combining artificial intelligence with career development expertise, offering a personalised, data-driven approach to job readiness. It functions as a comprehensive career coach, accessible anytime and anywhere.
Key Features That Set CareerSense Apart
CareerSense offers a comprehensive suite of features designed to empower students throughout their career journey. Its AI-driven VIPS profiling evaluates Values, Interests, Personality, and Skills to deliver personalised career recommendations aligned with individual strengths and aspirations. The smart resume builder provides real-time scoring and improvement tips, while the job-matching algorithm connects students to roles that fit their unique profiles. Through integrated access, students can RSVP for events, schedule advisory sessions, and apply for internships and job listings seamlessly. Additionally, the Employability Index measures job readiness and works alongside skill gap analysis and tailored course recommendations to help students stay competitive in today’s dynamic job market.
The Bigger Picture: Empowering Future-Ready Graduates
The future of work is shaped by constant change, technological disruption, and global connectivity. Employers seek individuals who are adaptable, self-aware, and equipped with relevant skills. CareerSense empowers students to take ownership of their career journey, understand their strengths, identify gaps, and build competencies that matter in the real world.
This initiative reflects SIM’s commitment to lifelong learning and employability, ensuring graduates are not only job-ready but future-ready. In a competitive market, CareerSense positions SIM learners as confident, agile professionals prepared to lead in the digital economy.
References:
- Introducing CareerSense: Your All-in-One Personalised Career Buddy On-The-Go – https://www.sim.edu.sg/articles-inspirations/introducing-careersense-your-all-in-one-personalised-career-buddy-on-the-go
- Career Service – https://www.sim.edu.sg/degrees-diplomas/life-at-sim/career-services
- SIM Career Sense App (Google Play Store) – https://play.google.com/store/apps/details?id=sg.edu.sim.careersense&hl=en-US&pli=1
- SIM Career Sense App (Apple Store) – https://apps.apple.com/sg/app/sim-careersense/id1641839680
- Introducing CareerSense: Your Guide to Career Success After Graduation – https://regional.simge.edu.sg/en/introducing-careersense-your-guide-to-career-success-after-graduation/
Hashtag: #SIMGlobalEducation #SIMGE #GlobalEducation #InternationalDegree #CareerReady #FutureSkills
The issuer is solely responsible for the content of this announcement.
About SIM Global Education
SIM Global Education (SIM GE) is a leading private education institution in Singapore and the region. We offer more than 140 academic programmes ranging from diplomas and graduate diploma programmes to bachelor’s and master’s degree programmes with some of the world’s most reputable universities from Australia, Canada, Europe, United Kingdom, and the United States. SIM GE’s cohort is made up of 16,000 full- and part-time students and adult learners, of which approximately 36% are international students hailing from over 50 countries.
SIM GE’s holistic learning approach and culturally diverse learning environment aim to equip students with knowledge, industry skills and employability competencies, as well as a global perspective to succeed as future leaders in a fast-changing, technologically driven world.
For more information on SIM Global Education, visit sim.edu.sg
Hong Kong and Macau Organisations Honoured for Outstanding Achievements ESG-led Business for a Sustainable Future
HONG KONG SAR – Media OutReach Newswire – 19 December 2025 – With global acceleration towards sustainable development and rising expectations from investors and stakeholders for responsible business practices, Hong Kong and Macau enterprises in recent years have been actively integrating Environmental, Social and Governance (ESG) vision into their business strategies to drive green transformation and high-quality growth. Organised by Television Broadcasts Limited (TVB) and co-organised by the Hong Kong Productivity Council, the TVB ESG Awards 2025 (the Awards) aim to recognise and commend enterprises and organisations that have demonstrated outstanding performance in ESG and sustainable development. Now in its fourth edition, this annual flagship event recognise outstanding organisations and their achievements in ESG practices over the past year.
The ceremony was officiated by Mr. Michael WONG, GBS, JP, Deputy Financial Secretary; Dr. LAM Ching-choi, GBS, JP, Non-official Member of the Executive Council & Chairman of the Council for Carbon Neutrality & Sustainable Development; Mr. SIU Sai Wo, General Manager (Business Operations), Television Broadcasts Limited; and Dr. Lawrence CHEUNG Chi-chong, Chief Technology Officer, Hong Kong Productivity Council. Following the Green Summit held in July this year, the presentation ceremony also featured sharing sessions, inviting industry leaders and experts to exchange the latest trends and practical experience. In addition, the enhanced matching sessions enabled enterprises to connect with numerous attendees through exhibition booths to promote cross-sector collaboration and knowledge sharing.
Diverse Award Categories Recognise ESG Efforts of Hong Kong and Macau Industries
This year’s Awards include the “Outstanding ESG Award”, “Best in ESG Practices”, “Best in ESG Report”, “ESG Environmental Innovative Technology Award” and “ESG Social Innovative Technology Award”. Entries were open to five groups, namely large, medium, small market capitalisation/ GEM listed companies, as well as non-listed companies and non-profit organisations, to recognise the achievements of enterprises of different scales in ESG practices, reporting and innovation. To identify outstanding performers, a cross-sector professional judging panel appointed by TVB were responsible for assessing entries, using clear and diversified selection criteria that mainly cover five areas: environment, social, corporate governance, sustainability strategy, corporate information disclosure and communication.
Additionally, a new “Greater Bay Area ESG Excellence Enterprise Award (Macau SAR)” has been introduced this year to recognise Macau enterprises and organisations with outstanding ESG performance that actively promote sustainable development in the Macau community. Furthermore, to enhance and recognise the excellent performance of small and medium-sized enterprises (SMEs) in ESG practices and innovation, TVB has collaborated with the “ESG One” platform of the Hong Kong Productivity Council to launch the “SME ESG Excellence Award” this year. The award covers five areas: “Business Decarbonisation”, “Employee Care”, “Supply Chain Partnership”, “Sustainable Governance” and “ESG Technology Enhancement”, helping SMEs to progressively enhance their ESG performance. Organisations that did not receive the above ESG category awards but have actively performed and implemented ESG initiatives in various aspects will be eligible for nomination of “ESG Special Recognition Award – with Merit” or “ESG Special Recognition Award” in acknowledgement of their contributions.
Mr. Michael WONG, GBS, JP, Deputy Financial Secretary, said in his keynote speech, “Hong Kong possesses significant advantages in green economy transformation. As the city’s two major innovation and technology flagships, Hong Kong Science Park and Cyberport have now brought together over 270 green technology companies, representing growth of more than 80% compared to 2023, reflecting remarkably rapid development in recent years. Hong Kong can provide diversified investment and financing channels, enabling international capital to match with quality green projects. As of the end of September this year, there are over 200 SFC-authorised ESG funds with assets under management exceeding HKD1.1 trillion, demonstrating that investors are increasingly prioritising investment in sustainable development. The Government looks forward to continued collaboration with all of you to jointly build our sustainable future and make outstanding contributions to Hong Kong’s green economic development.”
Mr. SIU Sai Wo, General Manager (Business Operations), Television Broadcasts Limited, said, “The TVB ESG Awards 2025 received over 250 corporate entries this year, reflecting the growing importance of ESG for enterprises. We are grateful to all award-winning organisations and partners for their continued support of this flagship award. This year’s awardees excelled in ESG performance and set forward-looking models for the industry. TVB is actively supporting enterprises to devote resources to ESG development, incorporate sustainability into business decision-making and operations, and strengthen their sense of social responsibility. The Awards also provide a professional exchange platform for enterprises of different industries and scales to share their ESG strategies and tangible outcomes with a wider range of stakeholders.”
To help the public gain a more comprehensive understanding of the vision, mission and innovative strategies of various enterprises, the presentation ceremony featured sharing sessions. The judge Dr. Lawrence CHEUNG Chi-chong, Chief Technology Officer, Hong Kong Productivity Council, together with representatives from enterprises receiving the Outstanding ESG Award, exchanged practical insights. As the highest honour of this year’s Awards, the Outstanding ESG Award is conferred upon top-tier organisations in each category that have achieved the best performance in both “ESG Practices” and “ESG Report”. The award-winning enterprises shared their insights in the session titled “Partnering Across Sectors to Co-create a Low-carbon Future”:
- Ms. Jessica CHAN, Head of Sustainability of MTR Corporation, shared how MTR leverages its diversified business portfolio to drive carbon reduction and social inclusion in daily operations, thus encouraging business partners to enhance their ESG performance.
- Ms. Angel SZE, Company Secretary and Head of ESG Management Committee, Fosun International Limited, who shared how Fosun is driving innovation and global development to create value, while highlighting effective ESG practices for cross‑industry and cross‑regional enterprises.
- Ms. Connie LAU, Assistant General Manager, Legal Department, China State Construction Development Holdings Limited, who used examples of innovative applications to demonstrate the company’s breakthroughs and decarbonisation goals.
- Mr. Jonathan CHIU, President, Schneider Electric Hong Kong, who highlighted the company’s commitment as a global energy technology leader to driving efficiency and sustainability by electrifying, automating and digitalising industries, businesses and homes, contributing to Hong Kong’s low-carbon transition.
- Mr. Peter LEE, Chief Sustainability Officer, Airport Authority Hong Kong, elaborated on how the authority collaborates with business partners and extends the sustainability concept to the society and education sector.
- Mr. Oswald AU, Managing Director, Riskory Consultancy Limited, shared how SMEs can drive ESG through innovative solutions and practical actions, while leveraging mega event economy development to create greater impact.
Building on these insights, another sharing session titled “Building a Green and Sustainable Pathway: Advancing Liveable, Inclusive Smart Cities” invited Mr. Andy WONG, Senior Manager, Advocacy, Our Hong Kong Foundation, as moderator. He was joined by Ir. Franco CHEUNG, Director (Projects), Hong Kong Housing Society, Mr. Samuel KWONG, Senior Associate Director – ESG, Chinachem Group and Mr. Jeffery LOK, Managing Director, Kwan On Chemical Enterprise Co. Ltd., for in-depth discussions on topics such as decarbonisation planning, the application of green building technologies including Modular Integrated Construction (MiC), kitchen and grease trap waste oil recycling, exploring the roadmap for Hong Kong and Macau’s sustainable urban development and environmental benefits.
Strong Corporate Involvement Fosters Cross-Sector Connections
This year’s ceremony attracted enthusiastic participation from numerous enterprises and organisations, including listed companies, non-listed companies and non-profit organisations, signalling the local market’s increasing commitment to ESG. Enhanced matching sessions with exhibition booths were arranged before and after the ceremony, allowing participants to engage in in-depth exchanges on green technology solutions, sustainable development and eco-friendly materials, and to explore collaboration opportunities.
For the full list of award winners, please visit: https://www.tvbesg.com.hk/past-awards/esg-awards-2025
High resolution photos HERE
Hashtag: #TVBESGAwards #TVB #ESG #Corporate
The issuer is solely responsible for the content of this announcement.
About TVB ESG
Since 2022, TVB ESG has been committed to building a professional exchange platform for local sustainable development, promoting a deeper understanding, implementation, and strategic development of Environmental, Social and Governance (ESG) issues among businesses and different sectors of society. TVB ESG works closely with various organisations to foster cross-sector collaboration, help enterprises expand their professional networks and strengthen industry connections, while enhancing their visibility in the market and industry through diverse channels, thereby amplifying their impact in the ESG field.
To enhance industry exchange and promote a culture of sustainability, TVB ESG organises three core events every year, the Green Forum, the Green Summit and the “TVB ESG Awards”. These events aim to focus on key environmental issues and emerging trends, bringing together industry leaders and experts to provide forward-looking insights for enterprises, promote knowledge sharing, and facilitate the exchange of best practices. Through the “TVB ESG Awards”, TVB ESG also recognises enterprises and organisations with outstanding achievements in sustainable development, encouraging the industry to continuously implement and elevate ESG standards.
1. Work Injury Claims Data (Total: 1,032 Cases)
Sick Leave Distribution:
- 0 – 30 Days: 279 cases
- 31 – 100 Days: 323 cases
- 101 – 300 Days: 261 cases
- 301 – 700 Days: 145 cases
- 701 – 1,000 Days: 18 cases
- 1,001 – 2,000 Days: 3 cases
- Over 2,000 Days: 3 cases
Summary: Over 58% of cases involve fewer than 100 days of sick leave, indicating that minor injuries remain the norm. However, extreme cases exceeding 2,000 days highlight the dire need for long-term legal and financial support for severely injured workers.
Assessment of Earning Capacity:
- 0% – 4%: 745 cases
- 5% – 14%: 188 cases
- 15% – 34%: 52 cases
- 35% – 64%: 11 cases
- 65% – 94%: 10 cases
- 95% – 100%: 26 cases
Summary: A “pyramid” distribution is observed, with 72% involving minor impairments. Yet, the 26 cases of near-total disability (95-100%) underscore the catastrophic impact of high-risk workplace accidents on families.
Estimated Results:
- HK$0 – $50,000: 381 cases
- HK$50,001 – $100,000: 226 cases
- HK$100,001 – $200,000: 147 cases
- HK$200,001 – $500,000: 109 cases
- HK$500,001 – $1,000,000: 125 cases
- HK$1,000,001 – $2,000,000: 31 cases
- HK$2,000,001 – $5,000,000: 13 cases
Summary: 16% of inquiries yield estimates above HK$500,000. These cases often involve complex future loss of earnings, signaling a high demand for specialized legal advocacy in high-value claims.
2. Traffic Accident Claims Data (Total: 868 Cases)
Injured Body Parts:
- Back / Spine: 176 cases
- Lower Back / Hips: 118 cases
- Head: 112 cases
- Shoulder: 111 cases
- Neck: 105 cases
- Leg: 104 cases
- Knee: 74 cases
- Arm: 68 cases
Summary: Back and spine injuries are the most frequent, often resulting from whiplash in rear-end collisions. These injuries are critical for PSLA (Pain, Suffering, and Loss of Amenities) evaluations in civil court.
Nature of Injuries:
- Sprain: 241 cases
- Fracture: 180 cases
- Contusion: 169 cases
- Nerve / Brain: 139 cases
- Internal: 74 cases
- Dislocation: 65 cases
Summary: While sprains are most common, the high number of nerve and brain injuries (139 cases) is concerning, as these often lead to permanent functional impairment.
Estimated Results:
- HK$0 – $100,000: 422 cases
- HK$100,001 – $200,000: 162 cases
- HK$200,001 – $500,000: 179 cases
- HK$500,001 – $1,000,000: 98 cases
- HK$1,000,001 – $2,000,000: 5 cases
- HK$2,000,001 – $10,000,000: 0 cases
- Over HK$10,000,000: 2 cases
Summary: Traffic claims show extreme polarization. While most stay below HK
$100k, two cases exceeded HK$ 10 million, reflecting the massive social cost of life-altering road collisions.
Mandatory Disclaimer
IMPORTANT: All compensation figures are generated by the “AI Compensation Calculator” based on user input. These are preliminary estimates only and not final actual compensation amounts. Final payouts depend on court rulings, liability apportionment, and medical evidence. Victims must seek formal legal advice from practicing lawyers.
Hashtag: #HKAccidentLawyers #HKCivilClaim #PersonalInjury #WorkInjury #CivilClaims #ClaimsData
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking7 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn